Eton Pharmaceuticals Ownership 2024 | Who Owns Eton Pharmaceuticals Now?
Institutional Ownership
31.94%
Insider Ownership
5.39%
Retail Ownership
62.68%
Institutional Holders
47.00
Eton Pharmaceuticals Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| OPALEYE MANAGEMENT INC. | 9.30% | 1.80% | 2,395,000 | -50,781 | -2.08% | 7,879,550 | Jun 30, 2024 |
| VANGUARD GROUP INC | 3.99% | 0.00% | 1,027,688 | - | - | 3,381,093 | Jun 30, 2024 |
| NANTAHALA CAPITAL MANAGEMENT, LLC | 3.65% | 0.18% | 940,733 | 940,733 | 100.00% | 3,095,012 | Jun 30, 2024 |
| WESTSIDE INVESTMENT MANAGEMENT, INC. | 2.27% | 0.44% | 585,400 | 11,440 | 1.99% | 1,925,973 | Jun 30, 2024 |
| ACUITAS INVESTMENTS, LLC | 2.25% | 1.02% | 579,960 | - | - | 1,908,068 | Jun 30, 2024 |
| PARADIGM CAPITAL MANAGEMENT INC/NY | 1.16% | 0.04% | 300,000 | - | - | 987,000 | Jun 30, 2024 |
| BLACKROCK INC. | 1.10% | - | 282,389 | -563 | -0.20% | 929,060 | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.98% | 0.02% | 253,362 | - | - | 833,561 | Jun 30, 2024 |
| PARKMAN HEALTHCARE PARTNERS LLC | 0.98% | 0.11% | 253,197 | 54,029 | 27.13% | 833,018 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.93% | 0.00% | 240,331 | 6,164 | 2.63% | 790,884 | Jun 30, 2024 |
| ARISTIDES CAPITAL LLC | 0.78% | 0.19% | 200,000 | 200,000 | 100.00% | 658,000 | Jun 30, 2024 |
| THOMPSON SIEGEL & WALMSLEY LLC | 0.50% | 0.01% | 127,724 | 127,724 | 100.00% | 420,000 | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.47% | 0.00% | 120,574 | -35,812 | -22.90% | 395,000 | Jun 30, 2024 |
| STONEPINE CAPITAL MANAGEMENT, LLC | 0.43% | 0.33% | 110,000 | 110,000 | 100.00% | 361,900 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.41% | 0.00% | 106,500 | 41,469 | 63.77% | 350,385 | Jun 30, 2024 |
| STATE STREET CORP | 0.32% | - | 81,403 | - | - | 267,816,000 | Jun 30, 2024 |
| BANK OF NEW YORK MELLON CORP | 0.29% | - | 74,491 | - | - | 245,076 | Jun 30, 2024 |
| NORTHERN TRUST CORP | 0.23% | - | 59,849 | -1,281 | -2.10% | 196,903,000 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.22% | - | 57,503 | -61,352 | -51.62% | 189,185 | Jun 30, 2024 |
| SCHONFELD STRATEGIC ADVISORS LLC | 0.20% | 0.00% | 50,917 | -45,952 | -47.44% | 167,516 | Jun 30, 2024 |
Eton Pharmaceuticals's largest institutional shareholder is OPALEYE MANAGEMENT INC., holding 9.30% of the company's total share outstanding, currently valued at $7.88M. The top 10 institutional shareholders own together 26.62% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| OPALEYE MANAGEMENT INC. | 9.30% | 1.80% | 2,395,000 | -50,781 | -2.08% | 7,879,550 | Jun 30, 2024 |
| ACUITAS INVESTMENTS, LLC | 2.25% | 1.02% | 579,960 | - | - | 1,908,068 | Jun 30, 2024 |
| WESTSIDE INVESTMENT MANAGEMENT, INC. | 2.27% | 0.44% | 585,400 | 11,440 | 1.99% | 1,925,973 | Jun 30, 2024 |
| STONEPINE CAPITAL MANAGEMENT, LLC | 0.43% | 0.33% | 110,000 | 110,000 | 100.00% | 361,900 | Jun 30, 2024 |
| ARISTIDES CAPITAL LLC | 0.78% | 0.19% | 200,000 | 200,000 | 100.00% | 658,000 | Jun 30, 2024 |
| NANTAHALA CAPITAL MANAGEMENT, LLC | 3.65% | 0.18% | 940,733 | 940,733 | 100.00% | 3,095,012 | Jun 30, 2024 |
| PARKMAN HEALTHCARE PARTNERS LLC | 0.98% | 0.11% | 253,197 | 54,029 | 27.13% | 833,018 | Jun 30, 2024 |
| PARADIGM CAPITAL MANAGEMENT INC/NY | 1.16% | 0.04% | 300,000 | - | - | 987,000 | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.98% | 0.02% | 253,362 | - | - | 833,561 | Jun 30, 2024 |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 0.11% | 0.02% | 27,252 | -51,361 | -65.33% | 89,659 | Jun 30, 2024 |
| QUANTUM PRIVATE WEALTH, LLC | 0.04% | 0.01% | 11,500 | - | - | 37,835 | Jun 30, 2024 |
| CHICAGO TRUST CO NA | 0.06% | 0.01% | 16,700 | - | - | 54,943 | Jun 30, 2024 |
| THOMPSON SIEGEL & WALMSLEY LLC | 0.50% | 0.01% | 127,724 | 127,724 | 100.00% | 420,000 | Jun 30, 2024 |
| XTX TOPCO LTD | 0.05% | 0.00% | 11,739 | -2,364 | -16.76% | 38,621 | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.47% | 0.00% | 120,574 | -35,812 | -22.90% | 395,000 | Jun 30, 2024 |
| SCHONFELD STRATEGIC ADVISORS LLC | 0.20% | 0.00% | 50,917 | -45,952 | -47.44% | 167,516 | Jun 30, 2024 |
| ADAR1 CAPITAL MANAGEMENT, LLC | 0.00% | 0.00% | 1,200 | 1,200 | 100.00% | 3,948 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.41% | 0.00% | 106,500 | 41,469 | 63.77% | 350,385 | Jun 30, 2024 |
| CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 0.14% | 0.00% | 34,847 | -4,450 | -11.32% | 114,647 | Jun 30, 2024 |
| BLAIR WILLIAM & CO/IL | 0.13% | 0.00% | 34,500 | -2,479 | -6.70% | 113,505 | Jun 30, 2024 |
The largest Eton Pharmaceuticals shareholder by % of total assets is OPALEYE MANAGEMENT INC.. The company owns 2.40M shares of Eton Pharmaceuticals (ETON), representing 1.80% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| NANTAHALA CAPITAL MANAGEMENT, LLC | 3.65% | 0.18% | 940,733 | 940,733 | 100.00% | 3,095,012 | Jun 30, 2024 |
| ARISTIDES CAPITAL LLC | 0.78% | 0.19% | 200,000 | 200,000 | 100.00% | 658,000 | Jun 30, 2024 |
| THOMPSON SIEGEL & WALMSLEY LLC | 0.50% | 0.01% | 127,724 | 127,724 | 100.00% | 420,000 | Jun 30, 2024 |
| STONEPINE CAPITAL MANAGEMENT, LLC | 0.43% | 0.33% | 110,000 | 110,000 | 100.00% | 361,900 | Jun 30, 2024 |
| PARKMAN HEALTHCARE PARTNERS LLC | 0.98% | 0.11% | 253,197 | 54,029 | 27.13% | 833,018 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.41% | 0.00% | 106,500 | 41,469 | 63.77% | 350,385 | Jun 30, 2024 |
| WESTSIDE INVESTMENT MANAGEMENT, INC. | 2.27% | 0.44% | 585,400 | 11,440 | 1.99% | 1,925,973 | Jun 30, 2024 |
| UBS GROUP AG | 0.04% | - | 11,018 | 9,058 | 462.14% | 36,249 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.93% | 0.00% | 240,331 | 6,164 | 2.63% | 790,884 | Jun 30, 2024 |
| ADAR1 CAPITAL MANAGEMENT, LLC | 0.00% | 0.00% | 1,200 | 1,200 | 100.00% | 3,948 | Jun 30, 2024 |
| ADVISOR GROUP HOLDINGS, INC. | 0.00% | - | 300 | 300 | 100.00% | 987 | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | 0.00% | - | 183 | 183 | 100.00% | 602 | Jun 30, 2024 |
| MORGAN STANLEY | 0.00% | - | 192 | 154 | 405.26% | 632 | Jun 30, 2024 |
| BNP PARIBAS ARBITRAGE, SNC | 0.00% | - | 350 | - | - | 1,152 | Jun 30, 2024 |
| LINDBROOK CAPITAL, LLC | - | - | 4 | - | - | 13 | Jun 30, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.05% | - | 13,239 | - | - | 43,556 | Jun 30, 2024 |
| DIMENSIONAL FUND ADVISORS LP | 0.04% | - | 10,564 | - | - | 34,755 | Jun 30, 2024 |
| STATE STREET CORP | 0.32% | - | 81,403 | - | - | 267,816,000 | Jun 30, 2024 |
| RAYMOND JAMES & ASSOCIATES | 0.04% | - | 10,250 | - | - | 33,723 | Jun 30, 2024 |
| BANK OF NEW YORK MELLON CORP | 0.29% | - | 74,491 | - | - | 245,076 | Jun 30, 2024 |
As of Jun 30 2024, Eton Pharmaceuticals's largest institutional buyer is NANTAHALA CAPITAL MANAGEMENT, LLC. The company purchased 940.73K stocks of ETON, valued at $3.10M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | 0.22% | - | 57,503 | -61,352 | -51.62% | 189,185 | Jun 30, 2024 |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 0.11% | 0.02% | 27,252 | -51,361 | -65.33% | 89,659 | Jun 30, 2024 |
| OPALEYE MANAGEMENT INC. | 9.30% | 1.80% | 2,395,000 | -50,781 | -2.08% | 7,879,550 | Jun 30, 2024 |
| SCHONFELD STRATEGIC ADVISORS LLC | 0.20% | 0.00% | 50,917 | -45,952 | -47.44% | 167,516 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | - | - | 4 | -44,610 | -99.99% | 14 | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.47% | 0.00% | 120,574 | -35,812 | -22.90% | 395,000 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | - | - | - | -19,155 | -100.00% | - | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.06% | 0.00% | 16,485 | -15,305 | -48.14% | 54,236 | Jun 30, 2024 |
| SQUAREPOINT OPS LLC | 0.16% | 0.00% | 41,255 | -7,838 | -15.97% | 135,729 | Jun 30, 2024 |
| CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 0.14% | 0.00% | 34,847 | -4,450 | -11.32% | 114,647 | Jun 30, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.01% | 0.00% | 3,638 | -3,955 | -52.09% | 11,969 | Jun 30, 2024 |
| BLAIR WILLIAM & CO/IL | 0.13% | 0.00% | 34,500 | -2,479 | -6.70% | 113,505 | Jun 30, 2024 |
| XTX TOPCO LTD | 0.05% | 0.00% | 11,739 | -2,364 | -16.76% | 38,621 | Jun 30, 2024 |
| TRUVESTMENTS CAPITAL LLC | - | - | - | -1,848 | -100.00% | - | Jun 30, 2024 |
| WELLS FARGO & COMPANY/MN | - | - | - | -1,425 | -100.00% | - | Jun 30, 2024 |
| NORTHERN TRUST CORP | 0.23% | - | 59,849 | -1,281 | -2.10% | 196,903,000 | Jun 30, 2024 |
| LAZARD ASSET MANAGEMENT LLC | - | - | - | -576 | -100.00% | - | Jun 30, 2024 |
| BLACKROCK INC. | 1.10% | - | 282,389 | -563 | -0.20% | 929,060 | Jun 30, 2024 |
| ROYAL BANK OF CANADA | 0.00% | - | 747 | -18 | -2.35% | 2,000 | Jun 30, 2024 |
| ACUITAS INVESTMENTS, LLC | 2.25% | 1.02% | 579,960 | - | - | 1,908,068 | Jun 30, 2024 |
As of Jun 30 2024, Eton Pharmaceuticals's biggest institutional seller is GOLDMAN SACHS GROUP INC. The company sold -61.35K shares of ETON, valued at $189.19K.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| NANTAHALA CAPITAL MANAGEMENT, LLC | 3.65% | 0.18% | 940,733 | 940,733 | 100.00% | 3,095,012 | Jun 30, 2024 |
| ARISTIDES CAPITAL LLC | 0.78% | 0.19% | 200,000 | 200,000 | 100.00% | 658,000 | Jun 30, 2024 |
| THOMPSON SIEGEL & WALMSLEY LLC | 0.50% | 0.01% | 127,724 | 127,724 | 100.00% | 420,000 | Jun 30, 2024 |
| STONEPINE CAPITAL MANAGEMENT, LLC | 0.43% | 0.33% | 110,000 | 110,000 | 100.00% | 361,900 | Jun 30, 2024 |
| ADAR1 CAPITAL MANAGEMENT, LLC | 0.00% | 0.00% | 1,200 | 1,200 | 100.00% | 3,948 | Jun 30, 2024 |
| ADVISOR GROUP HOLDINGS, INC. | 0.00% | - | 300 | 300 | 100.00% | 987 | Jun 30, 2024 |
Eton Pharmaceuticals's largest new institutional shareholder by number of shares is NANTAHALA CAPITAL MANAGEMENT, LLC, purchased 940.73K shares, valued at $3.10M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| JPMORGAN CHASE & CO | - | - | - | -19,155 | -100.00% | - | Jun 30, 2024 |
| TRUVESTMENTS CAPITAL LLC | - | - | - | -1,848 | -100.00% | - | Jun 30, 2024 |
| WELLS FARGO & COMPANY/MN | - | - | - | -1,425 | -100.00% | - | Jun 30, 2024 |
| LAZARD ASSET MANAGEMENT LLC | - | - | - | -576 | -100.00% | - | Jun 30, 2024 |
Eton Pharmaceuticals's largest sold out institutional shareholder by shares sold is JPMORGAN CHASE & CO, sold -19.16K shares, valued at -, as of undefined.
Eton Pharmaceuticals Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| PARADIGM FUNDS | 1.15% | 300,000 | - | - | Mar 31, 2024 |
| Starboard Investment Trust | 0.77% | 449,438 | - | - | Feb 29, 2024 |
| BRIDGEWAY FUNDS INC | 0.10% | 246,462 | - | - | Mar 28, 2024 |
| VANGUARD VALLEY FORGE FUNDS | 0.03% | 13,900 | - | - | Mar 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.00% | 2,467 | - | - | Mar 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.00% | 23,833 | - | - | Mar 31, 2024 |
| FIRST TRUST EXCHANGE-TRADED FUND | 0.00% | 28,080 | - | - | Mar 31, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 989,297 | -307,580 | -23.72% | Mar 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 212,457 | 6,001 | 2.91% | Feb 29, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 15,500 | - | - | Mar 31, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 1,302 | - | - | Mar 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 13,239 | - | - | Jan 31, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 7,824 | - | - | Mar 31, 2024 |
| SunAmerica Specialty Series | 0.00% | 122 | - | - | Apr 30, 2021 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 22,639 | 12,839 | 131.01% | Jan 31, 2024 |
| RUSSELL INVESTMENT CO | 0.00% | 36,079 | - | - | Jan 31, 2024 |
| NORTHERN FUNDS | 0.00% | 8,409 | - | - | Mar 28, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 3,000 | - | - | Mar 31, 2024 |
| FIDELITY SALEM STREET TRUST | 0.00% | 131,383 | - | - | Mar 31, 2024 |
| ProFunds | 0.00% | 369 | - | - | Mar 31, 2024 |
| VALIC Co I | 0.00% | 8,106 | - | - | Feb 29, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 54,356 | - | - | Feb 29, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 700 | - | - | Mar 28, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 2,795 | - | - | Mar 31, 2024 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 12,587 | - | - | Mar 31, 2024 |
| ALLSPRING MASTER TRUST | 0.00% | 711 | - | - | Feb 29, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 2,453 | - | - | Jan 31, 2024 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 8,437 | 2,561 | 43.58% | Jan 31, 2024 |
| TIAA-CREF FUNDS | 0.00% | 24,617 | - | - | Mar 31, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 814 | - | - | Feb 29, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 151 | - | - | Feb 29, 2024 |
| SUNAMERICA SERIES TRUST | 0.00% | 1,847 | - | - | Mar 31, 2024 |
| Dimensional ETF Trust | 0.00% | 1,327 | -8 | -0.60% | Jan 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 3,235 | - | - | Mar 31, 2024 |
| iSHARES TRUST | 0.00% | 43,911 | -1,152 | -2.56% | Mar 31, 2024 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 2,073 | - | - | Dec 31, 2023 |
| PACIFIC SELECT FUND | 0.00% | 6,829 | - | - | Mar 31, 2024 |
| Bridge Builder Trust | 0.00% | 6,844 | - | - | Mar 31, 2024 |
| PRINCIPAL FUNDS, INC. | 0.00% | 3,458 | - | - | Feb 29, 2024 |
| BlackRock Variable Series Funds, Inc. | 0.00% | 1,911 | - | - | Mar 31, 2024 |
| John Hancock Funds II | 0.00% | 3,599 | - | - | Feb 29, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 300 | 41 | 15.83% | Mar 31, 2024 |
| BLACKROCK FUNDS | 0.00% | 831 | - | - | Mar 28, 2024 |
Eton Pharmaceuticals's largest mutual fund holder by % of total assets is "PARADIGM FUNDS", owning 300.00K shares, compromising 1.15% of its total assets.
Eton Pharmaceuticals Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 47 | 4.44% |
| 31 Mar, 24 | 45 | -22.41% |
| 31 Dec, 23 | 58 | 9.43% |
| 30 Sep, 23 | 53 | 51.43% |
| 30 Jun, 23 | 35 | -5.41% |
| 31 Mar, 23 | 37 | 15.63% |
| 31 Dec, 22 | 32 | 3.23% |
| 30 Sep, 22 | 31 | 3.33% |
| 30 Jun, 22 | 30 | -6.25% |
| 31 Mar, 22 | 32 | -5.88% |
| 31 Dec, 21 | 34 | -12.82% |
| 30 Sep, 21 | 39 | -20.41% |
| 30 Jun, 21 | 49 | -2.00% |
| 31 Mar, 21 | 50 | 8.70% |
| 31 Dec, 20 | 46 | 21.05% |
| 30 Sep, 20 | 38 | -7.32% |
| 30 Jun, 20 | 41 | 141.18% |
| 31 Mar, 20 | 17 | 21.43% |
| 31 Dec, 19 | 14 | - |
| 30 Sep, 19 | 14 | 40.00% |
| 30 Jun, 19 | 10 | -16.67% |
| 31 Mar, 19 | 12 | - |
| 31 Dec, 18 | 12 | - |
As of 30 Jun 24, 47 institutions are holding Eton Pharmaceuticals's shares, representing an increase of 4.44% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 8,228,308 | 14.56% |
| 31 Mar, 24 | 7,182,688 | 0.34% |
| 31 Dec, 23 | 7,158,411 | 3.75% |
| 30 Sep, 23 | 6,899,800 | 15.45% |
| 30 Jun, 23 | 5,976,427 | 2.36% |
| 31 Mar, 23 | 5,838,851 | -1.66% |
| 31 Dec, 22 | 5,937,571 | -6.42% |
| 30 Sep, 22 | 6,344,893 | 7.22% |
| 30 Jun, 22 | 5,917,391 | 2.69% |
| 31 Mar, 22 | 5,762,654 | 1.05% |
| 31 Dec, 21 | 5,702,935 | -3.86% |
| 30 Sep, 21 | 5,932,207 | -13.30% |
| 30 Jun, 21 | 6,841,874 | -22.12% |
| 31 Mar, 21 | 8,785,326 | 0.68% |
| 31 Dec, 20 | 8,725,619 | 24.02% |
| 30 Sep, 20 | 7,035,506 | 3.40% |
| 30 Jun, 20 | 6,804,017 | 14.01% |
| 31 Mar, 20 | 5,967,828 | 127.32% |
| 31 Dec, 19 | 2,625,337 | 15.27% |
| 30 Sep, 19 | 2,277,650 | 28.84% |
| 30 Jun, 19 | 1,767,833 | 17.77% |
| 31 Mar, 19 | 1,501,083 | 30.29% |
| 31 Dec, 18 | 1,152,124 | - |
Eton Pharmaceuticals (ETON) has 8.23M shares outstanding as of 30 Jun 24, up 14.56% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 31.94% | 4.09% |
| 31 Mar, 24 | 27.93% | 3.61% |
| 31 Dec, 23 | 27.83% | 3.83% |
| 30 Sep, 23 | 26.96% | 4.92% |
| 30 Jun, 23 | 23.41% | 4.47% |
| 31 Mar, 23 | 22.88% | 4.18% |
| 31 Dec, 22 | 23.39% | 3.74% |
| 30 Sep, 22 | 25.01% | 4.51% |
| 30 Jun, 22 | 23.55% | 4.54% |
| 31 Mar, 22 | 22.78% | 4.45% |
| 31 Dec, 21 | 22.62% | 4.11% |
| 30 Sep, 21 | 23.47% | 3.19% |
| 30 Jun, 21 | 27.14% | 2.10% |
| 31 Mar, 21 | 35.93% | 2.67% |
| 31 Dec, 20 | 36.65% | 3.28% |
| 30 Sep, 20 | 33.42% | 3.19% |
| 30 Jun, 20 | 32.39% | 2.99% |
| 31 Mar, 20 | 32.89% | 15.33% |
| 31 Dec, 19 | 14.65% | 9.02% |
| 30 Sep, 19 | 12.74% | 12.82% |
| 30 Jun, 19 | 9.97% | 13.55% |
| 31 Mar, 19 | 8.58% | 8.75% |
| 31 Dec, 18 | 9.90% | - |
As of 30 Jun 24, Eton Pharmaceuticals is held by 31.94% institutional shareholders, representing a 4.09% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 14 | - |
| 31 Mar, 24 | 14 | -54.84% |
| 31 Dec, 23 | 31 | -6.06% |
| 30 Sep, 23 | 33 | 135.71% |
| 30 Jun, 23 | 14 | -12.50% |
| 31 Mar, 23 | 16 | 33.33% |
| 31 Dec, 22 | 12 | 20.00% |
| 30 Sep, 22 | 10 | 25.00% |
| 30 Jun, 22 | 8 | -46.67% |
| 31 Mar, 22 | 15 | 7.14% |
| 31 Dec, 21 | 14 | -6.67% |
| 30 Sep, 21 | 15 | -34.78% |
| 30 Jun, 21 | 23 | 4.55% |
| 31 Mar, 21 | 22 | -38.89% |
| 31 Dec, 20 | 36 | 140.00% |
| 30 Sep, 20 | 15 | -57.14% |
| 30 Jun, 20 | 35 | 191.67% |
| 31 Mar, 20 | 12 | 9.09% |
| 31 Dec, 19 | 11 | -8.33% |
| 30 Sep, 19 | 12 | 71.43% |
| 30 Jun, 19 | 7 | -12.50% |
| 31 Mar, 19 | 8 | -33.33% |
| 31 Dec, 18 | 12 | - |
14 institutional shareholders have increased their position in ETON stock as of 30 Jun 24 compared to 14 in the previous quarter (a 0.00% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 15 | 15.38% |
| 31 Mar, 24 | 13 | 30.00% |
| 31 Dec, 23 | 10 | 66.67% |
| 30 Sep, 23 | 6 | 20.00% |
| 30 Jun, 23 | 5 | -37.50% |
| 31 Mar, 23 | 8 | 14.29% |
| 31 Dec, 22 | 7 | -12.50% |
| 30 Sep, 22 | 8 | -33.33% |
| 30 Jun, 22 | 12 | 33.33% |
| 31 Mar, 22 | 9 | - |
| 31 Dec, 21 | 9 | -25.00% |
| 30 Sep, 21 | 12 | -29.41% |
| 30 Jun, 21 | 17 | -5.56% |
| 31 Mar, 21 | 18 | 200.00% |
| 31 Dec, 20 | 6 | -64.71% |
| 30 Sep, 20 | 17 | 240.00% |
| 30 Jun, 20 | 5 | 25.00% |
| 31 Mar, 20 | 4 | 300.00% |
| 31 Dec, 19 | 1 | - |
| 30 Sep, 19 | 1 | - |
| 30 Jun, 19 | 1 | - |
| 31 Mar, 19 | 1 | - |
| 31 Dec, 18 | - | - |
15 institutional shareholders have reduced their position in ETON stock as of 30 Jun 24 compared to 13 in the previous quarter (a 15.38% increase).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 47 | 4.44% | 8,228,308 | 14.56% | 31.94% | 4.09% | 14 | - | 15 | 15.38% |
| 31 Mar, 24 | 45 | -22.41% | 7,182,688 | 0.34% | 27.93% | 3.61% | 14 | -54.84% | 13 | 30.00% |
| 31 Dec, 23 | 58 | 9.43% | 7,158,411 | 3.75% | 27.83% | 3.83% | 31 | -6.06% | 10 | 66.67% |
| 30 Sep, 23 | 53 | 51.43% | 6,899,800 | 15.45% | 26.96% | 4.92% | 33 | 135.71% | 6 | 20.00% |
| 30 Jun, 23 | 35 | -5.41% | 5,976,427 | 2.36% | 23.41% | 4.47% | 14 | -12.50% | 5 | -37.50% |
| 31 Mar, 23 | 37 | 15.63% | 5,838,851 | -1.66% | 22.88% | 4.18% | 16 | 33.33% | 8 | 14.29% |
| 31 Dec, 22 | 32 | 3.23% | 5,937,571 | -6.42% | 23.39% | 3.74% | 12 | 20.00% | 7 | -12.50% |
| 30 Sep, 22 | 31 | 3.33% | 6,344,893 | 7.22% | 25.01% | 4.51% | 10 | 25.00% | 8 | -33.33% |
| 30 Jun, 22 | 30 | -6.25% | 5,917,391 | 2.69% | 23.55% | 4.54% | 8 | -46.67% | 12 | 33.33% |
| 31 Mar, 22 | 32 | -5.88% | 5,762,654 | 1.05% | 22.78% | 4.45% | 15 | 7.14% | 9 | - |
| 31 Dec, 21 | 34 | -12.82% | 5,702,935 | -3.86% | 22.62% | 4.11% | 14 | -6.67% | 9 | -25.00% |
| 30 Sep, 21 | 39 | -20.41% | 5,932,207 | -13.30% | 23.47% | 3.19% | 15 | -34.78% | 12 | -29.41% |
| 30 Jun, 21 | 49 | -2.00% | 6,841,874 | -22.12% | 27.14% | 2.10% | 23 | 4.55% | 17 | -5.56% |
| 31 Mar, 21 | 50 | 8.70% | 8,785,326 | 0.68% | 35.93% | 2.67% | 22 | -38.89% | 18 | 200.00% |
| 31 Dec, 20 | 46 | 21.05% | 8,725,619 | 24.02% | 36.65% | 3.28% | 36 | 140.00% | 6 | -64.71% |
| 30 Sep, 20 | 38 | -7.32% | 7,035,506 | 3.40% | 33.42% | 3.19% | 15 | -57.14% | 17 | 240.00% |
| 30 Jun, 20 | 41 | 141.18% | 6,804,017 | 14.01% | 32.39% | 2.99% | 35 | 191.67% | 5 | 25.00% |
| 31 Mar, 20 | 17 | 21.43% | 5,967,828 | 127.32% | 32.89% | 15.33% | 12 | 9.09% | 4 | 300.00% |
| 31 Dec, 19 | 14 | - | 2,625,337 | 15.27% | 14.65% | 9.02% | 11 | -8.33% | 1 | - |
| 30 Sep, 19 | 14 | 40.00% | 2,277,650 | 28.84% | 12.74% | 12.82% | 12 | 71.43% | 1 | - |
| 30 Jun, 19 | 10 | -16.67% | 1,767,833 | 17.77% | 9.97% | 13.55% | 7 | -12.50% | 1 | - |
| 31 Mar, 19 | 12 | - | 1,501,083 | 30.29% | 8.58% | 8.75% | 8 | -33.33% | 1 | - |
| 31 Dec, 18 | 12 | - | 1,152,124 | - | 9.90% | - | 12 | - | - | - |
Eton Pharmaceuticals Insider Shareholders Trades
Open Market Insider Trades
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of Eton Pharmaceuticals's stock was made by Krempa David on Mar 08 2023, selling - shares at - per share (valued at -).
Eton Pharmaceuticals Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q1 2024 | 7 | - | - |
| Q1 2023 | 6 | 10 | 60.00% |
| Q3 2022 | 3 | - | - |
| Q2 2022 | - | 1 | - |
| Q1 2022 | 6 | - | - |
| Q4 2021 | - | 19 | - |
| Q3 2021 | 2 | 6 | 33.33% |
| Q2 2021 | 7 | 11 | 63.64% |
| Q1 2021 | - | - | - |
| Q4 2020 | 2 | - | - |
| Q1 2020 | 6 | - | - |
| Q3 2019 | 2 | - | - |
| Q2 2019 | 2 | - | - |
| Q1 2019 | 6 | - | - |
| Q4 2018 | 8 | 15 | 53.33% |
| Q4 2017 | - | - | - |
| Q2 2017 | - | 1 | - |
7 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Eton Pharmaceuticals's insiders, as of Q1 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q1 2024 | - | - | - |
| Q1 2023 | - | - | - |
| Q3 2022 | 1 | - | - |
| Q2 2022 | - | - | - |
| Q1 2022 | - | - | - |
| Q4 2021 | - | 19 | - |
| Q3 2021 | 2 | 6 | 33.33% |
| Q2 2021 | 1 | 11 | 9.09% |
| Q1 2021 | - | - | - |
| Q4 2020 | 2 | - | - |
| Q1 2020 | - | - | - |
| Q3 2019 | 2 | - | - |
| Q2 2019 | 2 | - | - |
| Q1 2019 | - | - | - |
| Q4 2018 | 6 | - | - |
| Q4 2017 | - | - | - |
| Q2 2017 | - | - | - |
As of Q1 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Eton Pharmaceuticals's stocks.
Eton Pharmaceuticals Peer Ownership
| Ticker | Company |
|---|---|
| NUVB | Nuvation Bio Inc. |
| GOSS | Gossamer Bio, Inc. |
| ALDX | Aldeyra Therapeutics, Inc. |
| ALEC | Alector, Inc. |
| TVTX | Travere Therapeutics, Inc. |
| INBX | Inhibrx, Inc. |
| BDTX | Black Diamond Therapeutics, Inc. |
| REPL | Replimune Group, Inc. |
| LIAN | LianBio |
| KRON | Kronos Bio, Inc. |
| CNTB | Connect Biopharma Holdings Limited |
| PASG | Passage Bio, Inc. |
| ELDN | Eledon Pharmaceuticals, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| TARS | Tarsus Pharmaceuticals, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| CELC | Celcuity Inc. |
| MACK | Merrimack Pharmaceuticals, Inc. |
| NVCT | Nuvectis Pharma, Inc. |
| ELVN | Enliven Therapeutics, Inc. |
| ELYM | Eliem Therapeutics, Inc. |
ETON Ownership FAQ
Who Owns Eton Pharmaceuticals?
Eton Pharmaceuticals is owned by institutional shareholders (31.94%), insiders (5.39%), and public (62.68%). The largest institutional shareholder of Eton Pharmaceuticals is OPALEYE MANAGEMENT INC. (9.30% of total shares) and the top mutual fund owner is PARADIGM FUNDS (1.15% of total shares).
Who are the major institutional shareholders of Eton Pharmaceuticals?
Eton Pharmaceuticals's major institutional shareholders are OPALEYE MANAGEMENT INC., VANGUARD GROUP INC, NANTAHALA CAPITAL MANAGEMENT, LLC, WESTSIDE INVESTMENT MANAGEMENT, INC., and ACUITAS INVESTMENTS, LLC. The top five shareholders own together 21.46% of the company's share outstanding.
How many Eton Pharmaceuticals shareholders are there?
As of Jun 2024, there are 47 institutional shareholders of Eton Pharmaceuticals.
What percentage of Eton Pharmaceuticals is owned by OPALEYE MANAGEMENT INC?
OPALEYE MANAGEMENT INC owns 2.4M shares of Eton Pharmaceuticals, representing 9.30% of the company's total shares outstanding, valued at $7.88M (as of Jun 2024).
What percentage of Eton Pharmaceuticals is owned by VANGUARD GROUP INC?
As of Jun 2024, VANGUARD GROUP INC holds 1.03M shares of Eton Pharmaceuticals (ETON), compromising 3.99% of the company, valued at $3.38M.
What percentage of Eton Pharmaceuticals is owned by NANTAHALA CAPITAL MANAGEMENT, LLC?
NANTAHALA CAPITAL MANAGEMENT, LLC is the third largest holder of Eton Pharmaceuticals. The company owns 940.73K of the company's shares outstanding (worth $3.1M).